國立高雄大學圖資館 |

Language: English

Back

Pharmaceutical regulatory environmen...

Al-Essa, Reem K.

Pharmaceutical regulatory environmentchallenges and opportunities in the Gulf Region /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Pharmaceutical regulatory environmentby Reem K. Al-Essa ... [et al.].
Reminder of title:	challenges and opportunities in the Gulf Region /
other author:	Al-Essa, Reem K.
Published:	Cham :Springer International Publishing :2015.
Description:	xiii, 236 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	PharmacyLaw and legislationMiddle East.
Online resource:	http://dx.doi.org/10.1007/978-3-319-17590-4
ISBN:	9783319175904 (electronic bk.)

Pharmaceutical regulatory environmentchallenges and opportunities in the Gulf Region /
Pharmaceutical regulatory environmentchallenges and opportunities in the Gulf Region /[electronic resource] :by Reem K. Al-Essa ... [et al.]. - Cham :Springer International Publishing :2015. - xiii, 236 p. :ill., digital ;24 cm.

1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.

The Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients' access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region. Reem Al-Essa BPharm MSc PhD was the Drug Registration and Release Superintendent, Kuwait Ministry of Health, Drug and Food Control Department, for 12 years during which time she completed her MBA with distinction. She later undertook the EU2P MSc in Pharmacovigilance and Pharmacoepidemiology. Dr Al-Essa has published six journal articles and abstracts related to pharmaceutical regulation in the Gulf region. Mohammed Hamdan Al-Rubaie BPharm MSc PhD is the Director of Drug Control, Directorate General of Pharmaceutical affairs and Drug Control, Oman Ministry of Health.He is a member of the GCC Central Registration Committee, and actively involved in many other GCC committees and working groups for the drafting of the GCC pharmaceutical regulations and policies. Dr Al-Rubaie was instrumental in forming the Pharmaceutical society in Oman and chaired it from 2010-2011. Stuart Walker BSc, PhD, MFPM FRSC FIBiol, FRCPath, is the Founder of the Centre for Medicines Research International, the Centre for Innovation in Regulatory Science and Professor of Pharmaceutical Medicine, University of Wales, Cardiff. During his research career in academia & industry, he has supervised many PhD programmes in clinical development, regulatory policies, the benefit/risk assessment of medicines and health technology assessment, co-authored 280 research papers and edited 25 books. He is frequently involved in the organisation of international meetings on key issues that concern the regulatory review of medicines and has lectured extensively throughout Europe, the USA, the Asia-Pacific Region, Latin America and the Middle East. Sam Salek PhD RPh FFPM MRPSGB MCMS FESCP is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek's research focuses mainly on four areas: development and application of patient-reported outcome measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 19 books and 600 journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.

ISBN: 9783319175904 (electronic bk.)

Standard No.: 10.1007/978-3-319-17590-4doiSubjects--Topical Terms:

725200
Pharmacy
--Law and legislation--Middle East.

LC Class. No.: RS67.M628

Dewey Class. No.: 615.1093

Pharmaceutical regulatory environmentchallenges and opportunities in the Gulf Region /
LDR:05041nmm a2200313 a 4500 001 469242
003 DE-He213
005 20160108100132.0
006 m d
007 cr nn 008maaau
008 160118s2015 gw s 0 eng d
020 $a 9783319175904 (electronic bk.)
020 $a 9783319175898 (paper)
024 7 $a 10.1007/978-3-319-17590-4 $2 doi
035 $a 978-3-319-17590-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RS67.M628
072 7 $a MBN $2 bicssc
072 7 $a MED078000 $2 bisacsh
082 0 4 $a 615.1093 $2 23
090 $a RS67.M628 $b P536 2015
245 0 0 $a Pharmaceutical regulatory environment $h [electronic resource] : $b challenges and opportunities in the Gulf Region / $c by Reem K. Al-Essa ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a xiii, 236 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
520 $a The Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients' access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region. Reem Al-Essa BPharm MSc PhD was the Drug Registration and Release Superintendent, Kuwait Ministry of Health, Drug and Food Control Department, for 12 years during which time she completed her MBA with distinction. She later undertook the EU2P MSc in Pharmacovigilance and Pharmacoepidemiology. Dr Al-Essa has published six journal articles and abstracts related to pharmaceutical regulation in the Gulf region. Mohammed Hamdan Al-Rubaie BPharm MSc PhD is the Director of Drug Control, Directorate General of Pharmaceutical affairs and Drug Control, Oman Ministry of Health.He is a member of the GCC Central Registration Committee, and actively involved in many other GCC committees and working groups for the drafting of the GCC pharmaceutical regulations and policies. Dr Al-Rubaie was instrumental in forming the Pharmaceutical society in Oman and chaired it from 2010-2011. Stuart Walker BSc, PhD, MFPM FRSC FIBiol, FRCPath, is the Founder of the Centre for Medicines Research International, the Centre for Innovation in Regulatory Science and Professor of Pharmaceutical Medicine, University of Wales, Cardiff. During his research career in academia & industry, he has supervised many PhD programmes in clinical development, regulatory policies, the benefit/risk assessment of medicines and health technology assessment, co-authored 280 research papers and edited 25 books. He is frequently involved in the organisation of international meetings on key issues that concern the regulatory review of medicines and has lectured extensively throughout Europe, the USA, the Asia-Pacific Region, Latin America and the Middle East. Sam Salek PhD RPh FFPM MRPSGB MCMS FESCP is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek's research focuses mainly on four areas: development and application of patient-reported outcome measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 19 books and 600 journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.
650 0 $a Pharmacy $x Law and legislation $z Middle East. $3 725200
650 0 $a Drugs $x Law and legislation $z Middle East. $3 725201
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Public Health. $3 320661
650 2 4 $a Pharmacotherapy. $3 615025
650 2 4 $a Medicine/Public Health, general. $3 273879
700 1 $a Al-Essa, Reem K. $3 725199
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-17590-4
950 $a Medicine (Springer-11650)